Iruxolum Mono

Collagenase clostridium histolyticum, the active ingredient in Iruxolum Mono, is an enzyme (collagenase) presented as a topical formulation for topical use. It facilitates enzymatic debridement of necrotic tissue in chronic wounds and other dermatologic conditions.

GNH USA supplies Iruxolum Mono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iruxolum Mono, a collagenase enzyme, is employed in dermatology for enzymatic debridement of necrotic tissue. - Chronic wound debridement: removes necrotic tissue to promote healing in long‑standing ulcers. - Pressure injury management: facilitates debridement of dead tissue in pressure ulcers. - Dermatologic debridement: prepares chronic skin lesions for further treatment by clearing extracellular matrix.

Local application of Iruxolum Mono may be associated with several adverse reactions.

Common Side Effects: - Redness at the application site - Mild pain or discomfort - Swelling of the treated area

Serious or Rare Side Effects: - Anaphylactic reaction - Extensive tissue necrosis beyond the intended area - Secondary infection at the wound site

Iruxolum Mono should be used with caution and according to prescriber guidance. - Contraindication: known hypersensitivity to collagenase or protease enzymes. - Use only on wounds with viable surrounding tissue; avoid healthy skin. - Monitor for signs of infection throughout treatment. - Do not apply over mucous membranes or open surgical sites. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid): - Concurrent topical antibiotics containing sulfonamides may increase local irritation. - Systemic immunosuppressants may alter wound‑healing response.

Moderate Interactions (Monitor Closely): - Use with other enzymatic debriding agents may increase risk of tissue damage. - Application over areas previously treated with radiation therapy may exacerbate skin reactions. - Combination with dressings high in silver may reduce enzyme activity.